A fully funded, platform-driven bet on a first-in-class, redosable human ATG that could move Type 1 Diabetes beyond insulin—if 2027 data hits.
Overview
SAB Biotherapeutics (SABS) is a clinical-stage biotech building fully human polyclonal antibody therapies using its proprietary DiversitAb™ platform, which leverages genetically engineered transchromosomic (Tc) cattle carrying a human artificial chromosome to generate large quantities of targeted human IgG without human donors. In late 2024–2025, the company strategically pivoted from a broader infectious disease pipeline toward autoimmune disease, concentrating on Type 1 Diabetes. Its lead asset, SAB-142 (fully human anti-thymocyte immunoglobulin; hATG), has advanced into the registrational Phase 2b SAFEGUARD trial in Stage 3 T1D (first patient dosed Dec 2025; data expected 2H 2027). The core differentiation versus traditional animal-derived ATG is safety and usability: Phase 1 data showed 0% serum sickness in 68 participants, supporting outpatient administration and the possibility of periodic redosing. Financially, SABS remains pre-commercial, with historical funding from grants/collabs (e.g., DoD/Navy for influenza/COVID programs), but it was materially de-risked by a $175M July 2025 private placement including Sanofi, extending runway to mid‑2028 and funding the pivotal study. The target market is large and growing (7MM T1D to ~$9.9B by 2033), and SAB-142 is positioned to address the largest segment (Stage 3) where disease modification is not yet approved.